NERVMinerva Neurosciences, Inc.
- GlobeNewswire
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the ...
- GlobeNewswire
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- GlobeNewswire
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- GlobeNewswire
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction ...
- Analyst Upgrades
Citizens Initiates Coverage On Minerva Neurosciences with Market Outperform Rating, Announces Price Target of $14
Citizens analyst Jason N. Butler initiates coverage on Minerva Neurosciences with a Market Outperform rating and announces Price Target of $14. ...
- GlobeNewswire
Minerva Announces Leadership Transition
BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- GlobeNewswire
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, ...
- GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Raises Price Target to $7
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences with a Neutral and raises the price target from $4 to $7. ...
- GlobeNewswire
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- GlobeNewswire
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- GlobeNewswire
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $4
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences with a Neutral and lowers the price target from $5 to $4. ...
- GlobeNewswire
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) ...
- GlobeNewswire
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone's clinical development and ...
- GlobeNewswire
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- ...
- GlobeNewswire
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - Minerva Neurosciences, Inc. (0001598646) (Filer)
Quarterly report [Sections 13 or 15(d)] ...
- SEC
10-K/A Form - [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] - Minerva Neurosciences, Inc. (0001598646) (Filer)
[Amend] Annual report [Section 13 and 15(d), not S-K Item 405] ...
- SEC
10-K/A Form - [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] - Minerva Neurosciences, Inc. (0001598646) (Filer)
[Amend] Annual report [Section 13 and 15(d), not S-K Item 405] ...
- SEC
8-K Form - Current report, item 8.01 - Minerva Neurosciences, Inc. (0001598646) (Filer)
Current report, item 8.01 ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $5 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Minerva Neurosciences with a Neutral and maintains $5 price target. ...
- GlobeNewswire
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- SEC
10-K Form - Annual report [Section 13 and 15(d), not S-K Item 405] - Minerva Neurosciences, Inc. (0001598646) (Filer)
Annual report [Section 13 and 15(d), not S-K Item 405] ...
- SEC
SC 13G/A Form - [Amend] Statement of Beneficial Ownership by Certain Investors - Minerva Neurosciences, Inc. (0001598646) (Subject)
[Amend] Statement of Beneficial Ownership by Certain Investors ...